GlassScriptPhysician profile
Li Huang
NPI 1568872075
$3,055.00
in general payments reported to CMS, 2019-2025
31 companies · $1,498 in 2025
The $1,498 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $21.88 · 2021: $239 · 2022: $351 · 2023: $511 · 2024: $93.21 · 2025: $1,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,102.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $653.79 | 2019-2025 | Ozempic, Rybelsus, Saxenda |
| Dexcom, INC. | $322.56 | 2021-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $239.49 | 2022-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $230.27 | 2021-2025 | Korlym |
| Lilly USA, LLC | $226.08 | 2025 | Jardiance, Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $196.51 | 2025 | Recorlev, Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $172.61 | 2019-2025 | Pifeltro |
| Amgen INC. | $166.12 | 2021-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.47 | 2025 | Jardiance |
| Pfizer INC. | $86.67 | 2022-2024 | |
| Madrigal Pharmaceuticals | $84.31 | 2025 | Rezdiffra |
| Paratek Pharmaceuticals, INC. | $73.45 | 2025 | Nuzyra |
| Melinta Therapeutics, LLC | $51.00 | 2025 | Orbactiv, Kimyrsa, Rezzayo |
| Astrazeneca Pharmaceuticals LP | $43.66 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $43.42 | 2023 | Xarelto |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $37.85 | 2021-2022 | |
| Insulet Corporation | $33.58 | 2021-2025 | Omnipod |
| Radius Health, INC. | $24.39 | 2025 | Tymlos |
| Horizon Therapeutics Plc | $23.89 | 2023 | Tepezza |
| Regeneron Healthcare Solutions, INC. | $23.82 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.70 | 2025 | |
| Viiv Healthcare Company | $22.52 | 2025 | Rukobia |
| Esperion Therapeutics, INC. | $22.52 | 2025 | Nexletol |
| Medtronic, INC. | $22.32 | 2025 | Minimed 780g |
| Althera Pharmaceuticals LLC | $21.88 | 2021 | |
| Aurinia Pharma U.S., INC. | $21.48 | 2021 | |
| Mannkind Corporation | $20.54 | 2025 | |
| Sanofi-Aventis U.S. LLC | $19.92 | 2023 | |
| Novartis Pharmaceuticals Corporation | $18.12 | 2022 | |
| Tolmar, INC. | $17.18 | 2025 | Jatenzo |
| Tandem Diabetes Care, INC. | $16.88 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Li Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.